Sage Journals: Discover world-class research

Abstract

The present study was designed as a 12-week, randomized, double-blind, placebo-controlled pilot study to evaluate the effectiveness and safety of donepezil in boys with fragile X syndrome. Twenty boys with fragile X syndrome were randomized to receive 12 weeks of treatment with either placebo or donepezil (2.5 mg daily for initial 4 weeks followed by 5 mg daily for next 8 weeks). The outcome measures included change in intelligence quotient scores on Stanford-Binet Intelligence Scale (Hindi adaptation by Kulshrestha), change in behavioral scores by Conners 3 Parent Rating Scale (Short) and Childhood Autism Rating Scale, safety, and tolerability of donepezil. The study failed to show significant difference in intelligence quotient and behavioral scales with donepezil therapy over 12 weeks. However, donepezil appeared to be safe and well tolerated.

Keywords

intellectual function donepezil fragile X syndrome cholinergic

Get full access to this article

View all access options for this article.

References

Backes

Genç

Schreck

. Cognitive and behavioral profile of fragile X boys: correlations to molecular data. Am J Med Genet. 2000;95(2):150–156.

Penagarikano

Mulle

Warren

. The pathophysiology of fragile X syndrome. Annu Rev Genomics Hum Genet. 2007;8:109–129.

Jin

Warren

. Understanding the molecular basis of fragile X syndrome. Hum Mol Genet. 2000;9(6):901–908.

Abitbol

Menini

Delezoide

. Nucleus basalis magnocellularis and hippocampus are the major sites of FMR-1 expression in the human fetal brain. Nat Genet. 1993;4(2):147–153.

D’Antuono

Merlo

Avoli

. Involvement of cholinergic and gabaergic systems in the fragile X knockout mice. Neuroscience. 2003;119(1):9–13.

Chang

Bray

. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol 2008;4(4):256–263.

Kesler

Lightbody

Reiss

. Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study. Am J Med Genet. A. 2009;149A(3):403–407.

Prasher

Huxley

Haque

. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer’s disease—pilot study. Int J Geriatr Psychiatry. 2002;17(3):270–278.

Johnson

Fahey

Chicoine

Chong

Gitelman

. Effects of donepezil on cognitive functioning in Down syndrome. Am J Ment Retard. 2003;108(6):367–372.

10.

Spiridigliozzi

Heller

Crissman

. Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series. Am J Med. Genet. A. 2007;143A(13):1408–1413.

11.

Niederhofer

. Donepezil also effective in the treatment of Tourette’s syndrome? Mov Disord. 2006;21(11):2027.

12.

Doyle

Frazier

Spencer

. Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. J Atten Disord. 2006;9(3):543–549.

13.

Chez

Buchanan

Becker

. Donepezil hydrochloride: a double-blind study in autistic children. J Pediatr Neurol. 2003;1(2):83–88.

14.

Kulshrestha

. Stanford-Binet Intelligence Scale: Hindi Adaptation of Third Revision–Form L-M. Allahabad, India: Manas; 1971.

15.

Conners

. Conners 3 Parent Rating Scale (Short). North Tonawanda, NY: Multi-Health Systems; 2008.

16.

Schopler

Reichler

Renner

. The Childhood Autism Rating Scale: CARS. Los Angeles, CA: Western Psychological Services; 1988.

17.

Mishra

Singh

. Kuppuswamy’s socioeconomic status scale—a revision. Indian J Pediatr. 2003;70(3):273–274.

Effectiveness and Safety of Donepezil in Boys With Fragile X Syndrome

Abstract

Keywords

Get full access to this article

References